These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 20222127)

  • 21. Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease.
    Liu ZJ; Yadav PK; Su JL; Wang JS; Fei K
    World J Gastroenterol; 2009 Dec; 15(46):5784-8. PubMed ID: 19998498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Innate and adaptive immunity in inflammatory bowel disease.
    Geremia A; Biancheri P; Allan P; Corazza GR; Di Sabatino A
    Autoimmun Rev; 2014 Jan; 13(1):3-10. PubMed ID: 23774107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting IL-23 and Th17-cytokines in inflammatory bowel diseases.
    De Nitto D; Sarra M; Cupi ML; Pallone F; Monteleone G
    Curr Pharm Des; 2010; 16(33):3656-60. PubMed ID: 21128900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease.
    Geremia A; Arancibia-Cárcamo CV; Fleming MP; Rust N; Singh B; Mortensen NJ; Travis SP; Powrie F
    J Exp Med; 2011 Jun; 208(6):1127-33. PubMed ID: 21576383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Compartmentalized expression of Th1 and Th17 cytokines in pediatric inflammatory bowel diseases.
    Verdier J; Begue B; Cerf-Bensussan N; Ruemmele FM
    Inflamm Bowel Dis; 2012 Jul; 18(7):1260-6. PubMed ID: 21994045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease.
    Verstockt B; Van Assche G; Vermeire S; Ferrante M
    Expert Opin Biol Ther; 2017 Jan; 17(1):31-47. PubMed ID: 27817215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoregulatory Pathways Involved in Inflammatory Bowel Disease.
    Fonseca-Camarillo G; Yamamoto-Furusho JK
    Inflamm Bowel Dis; 2015 Sep; 21(9):2188-93. PubMed ID: 26111210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases.
    Bunte K; Beikler T
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31295952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Decade of Th9 Cells: Role of Th9 Cells in Inflammatory Bowel Disease.
    Vyas SP; Goswami R
    Front Immunol; 2018; 9():1139. PubMed ID: 29881387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pivotal roles of the interleukin-23/T helper 17 cell axis in hepatitis B.
    Huang Z; van Velkinburgh JC; Ni B; Wu Y
    Liver Int; 2012 Jul; 32(6):894-901. PubMed ID: 22340646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delivery of IL-12p40 ameliorates DSS-induced colitis by suppressing IL-17A expression and inflammation in the intestinal mucosa.
    Kim DJ; Kim KS; Song MY; Seo SH; Kim SJ; Yang BG; Jang MH; Sung YC
    Clin Immunol; 2012 Sep; 144(3):190-9. PubMed ID: 22836084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Th17 Cells as Potential Probiotic Therapeutic Targets in Inflammatory Bowel Diseases.
    Owaga E; Hsieh RH; Mugendi B; Masuku S; Shih CK; Chang JS
    Int J Mol Sci; 2015 Sep; 16(9):20841-58. PubMed ID: 26340622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Batf-dependent Th17 cells critically regulate IL-23 driven colitis-associated colon cancer.
    Punkenburg E; Vogler T; Büttner M; Amann K; Waldner M; Atreya R; Abendroth B; Mudter J; Merkel S; Gallmeier E; Rose-John S; Neurath MF; Hildner K
    Gut; 2016 Jul; 65(7):1139-50. PubMed ID: 25838550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunopathogenesis of inflammatory bowel disease: current concepts.
    Bamias G; Cominelli F
    Curr Opin Gastroenterol; 2007 Jul; 23(4):365-9. PubMed ID: 17545770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in IBD pathogenesis: genetics and immunobiology.
    Shih DQ; Targan SR; McGovern D
    Curr Gastroenterol Rep; 2008 Dec; 10(6):568-75. PubMed ID: 19006613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Interleukin-23 / Interleukin-17 axis in intestinal inflammation.
    Maloy KJ
    J Intern Med; 2008 Jun; 263(6):584-90. PubMed ID: 18479257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases.
    Sarra M; Monteleone I; Stolfi C; Fantini MC; Sileri P; Sica G; Tersigni R; Macdonald TT; Pallone F; Monteleone G
    Inflamm Bowel Dis; 2010 Aug; 16(8):1332-9. PubMed ID: 20186935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease?
    Zhang Z; Hinrichs DJ; Lu H; Chen H; Zhong W; Kolls JK
    Int Immunopharmacol; 2007 Apr; 7(4):409-16. PubMed ID: 17321463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging immunological targets in inflammatory bowel disease.
    Monteleone G; Pallone F; MacDonald TT
    Curr Opin Pharmacol; 2011 Dec; 11(6):640-5. PubMed ID: 22000933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of cytokines in inflammatory bowel disease.
    Sanchez-Munoz F; Dominguez-Lopez A; Yamamoto-Furusho JK
    World J Gastroenterol; 2008 Jul; 14(27):4280-8. PubMed ID: 18666314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.